Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes

ABSTRACT: Rhabdomyosarcomas (RMS) are mesenchyme-derived tumors and the most common childhood soft tissue sarcomas. Treatment is intense, with a nevertheless poor prognosis for high-risk patients. Discovery of new therapies would benefit from additional preclinical models. Here we describe the generation of a collection of 19 pediatric RMS tumor organoid (tumoroid) models (success rate of 41%) comprising all major subtypes. For aggressive tumors, tumoroid models can often be established within four to eight weeks, indicating the feasibility of personalized drug screening. Molecular, genetic and histological characterization show that the models closely resemble the original tumors, with genetic stability over extended culture periods of up to six months. Importantly, drug screening reflects establis

SUBMITTER: Michael, T. Meister 

PROVIDER: S-SCDT-EMM-2022-16001 | biostudies-other |

REPOSITORIES: biostudies-other